http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102081987-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2017-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102081987-B1 |
| titleOfInvention | A novel Natural Killer cell line and use thereof |
| abstract | The present invention relates to novel natural killer cell lines and uses thereof, more specifically CD2, CD11a, CD25, CD45, CD54, CD56 and HLA-DR are positive; And CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ and TCRγδ are negative new natural killer cell lines and pharmaceutical compositions for treating cancer comprising the same. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022169291-A1 |
| priorityDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 897.